

10/511148 #2
DT04 Rec'd PCT/PTO 14 OCT 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Alan M. SAWYER et al.

: Mail Stop: PCT

Serial No. NEW

: Attorney Docket No. 2004_1542A

Filed October 14, 2004

METHOD FOR PRODUCING MONOCLONAL ANTIBODIES
[Corresponding to PCT/GB03/01684
Filed April 17, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication (*for U.S. National applications filed after June 30, 2003 and International applications that have entered U.S. National Stage after June 30, 2003*),
- each reference previously cited in the international application PCT/GB03/01684; and/or
- each reference previously cited in prior parent application Serial No. _____

1a. This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

10/511148
DT04 Rec'd PCT/PTO 14 OCT 2007

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. This Information Disclosure Statement is submitted
after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:
(1) the certification of paragraph 2 below is provided, **or**
(2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. This Information Disclosure Statement is submitted:
after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:
the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/511148
DT04 Rec'd PCT/PTO 14 OCT 2004

3. Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. a full or partial English language translation submitted herewith,
 - b. a foreign patent office search report (in the English language) submitted herewith,
 - c. the concise explanation contained in the specification of the present application at page,
 - d. the concise explanation set forth in the attached English language abstract,
 - e. the concise explanation set forth below or on a separate sheet attached to the reference:
5. A foreign patent office search report citing one or more of the references is enclosed along with the International Preliminary Examination Report and Written Opinion.

Respectfully submitted,

Alan M. SAWYER et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
October 14, 2004

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: October 14, 2004

ATTY DOCKET NO.
2004_1542ASERIAL NO.
NEW

10/511148

APPLICANT
Alan M. SAWYER et al.FILING DATE
October 14, 2004

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD	96 33735	10/1996	WO			
	AE	01 14425	3/2001	WO			
	AF	03 019192	3/2003	WO			
	AG						
	AH						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	M. F. Templin et al., "Protein microarray technology", Trends in Biotechnology, Elsevier Publications, Vol. 20, No. 4, April 1, 2002, pp. 160-166, XP004344214.
	AJ	A. Lueking et al., "Protein microarrays for gene expression and antibody screening", Analytical Biochemistry, Academic Press, Vol. 270, No. 1, May 1, 1999, pp. 103-111, XP000949937.
	AK	B. B. Haab et al., "Protein Microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions", Genome Biology, Vol. 2, No. 2, 2001, XP001147826.
	AL	P. Arenkov et al., "Protein microchips: use for immunoassay and enzymatic reactions", Analytical Biochemistry, Academic Press, Vol. 278, No. 2, February 15, 2000, pp. 123-131, XP002234264.
	AM	R. P. Ekins, "Ligand Assays: from electrophoresis to miniaturized microarrays", Clinical Chemistry, American Association for Clinical Chemistry, Vol. 44, No. 9, 1998, pp. 2015-2030, XP002939389.
	AN	
EXAMINER		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.